| 1. |
Mason RJ, Slutsky A, Murray JF, et al. Murray & Nadel’s textbook of respiratory medicine. 6th ed. Amsterdam: Elsevier, 2016: 1260-1274.
|
| 2. |
Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med, 2002, 166(2): 215-235.
|
| 3. |
Rodríguez Portal JA. Treatment of adult primary alveolar proteinosis. Arch Bronconeumol, 2015, 51(7): 344-349.
|
| 4. |
Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med, 2003, 349(26): 2527-2539.
|
| 5. |
Trapnell BC, Nakata K, Bonella F, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers, 2019, 5(1): 16.
|
| 6. |
Philippot Q, Cazes A, Borie R, et al. Secondary pulmonary alveolar proteinosis after lung transplantation: a single-centre series. Eur Respir J, 2017, 49(2): 1601369.
|
| 7. |
Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med, 2011, 105(12): 1908-1916.
|
| 8. |
Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med, 2008, 177(7): 752-762.
|
| 9. |
Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med, 2010, 182(10): 1292-1304.
|
| 10. |
Ishii H, Trapnell BC, Tazawa R, et al. Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis. Chest, 2009, 136(5): 1348-1355.
|
| 11. |
Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood, 2009, 113(11): 2547-2556.
|
| 12. |
Uchida K, Nakata K, Carey B, et al. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods, 2014, 402(1/2): 57-70.
|
| 13. |
Bai J, Xu J, Yang W, et al. A new scale to assess the severity and prognosis of pulmonary alveolar proteinosis. Can Respir J, 2016, 2016: 3412836.
|
| 14. |
Awab A, Khan MS, Youness HA. Whole lung lavage-technical details, challenges and management of complications. J Thorac Dis, 2017, 9(6): 1697-1706.
|
| 15. |
Seymour JF, Dunn AR, Vincent JM, et al. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med, 1996, 335(25): 1924-1925.
|
| 16. |
Khan A, Agarwal R, Aggarwal AN. Effectiveness of granulocyte-macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis: a meta-analysis of observational studies. Chest, 2012, 141(5): 1273-1283.
|
| 17. |
Leth S, Bendstrup E, Vestergaard H, et al. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. Respirology, 2013, 18(1): 82-91.
|
